Skip to content
BOE-A-2026-10040 ·8 May 2026 ·Resolution Medium impact
Subsidies

FEDER and ISCIII extend research evaluation agreement for rare diseases until 2026

The amendment and extension of the agreement between the Instituto de Salud Carlos III and the FEDER Foundation for evaluating research proposals on rare diseases submitted in 2025 is published. The agreement is signed on 27 April 2026 and published on 28 April 2026, in accordance with Article 48.8 of Law 40/2015. This extension allows the evaluation process to continue in this healthcare area.

In 2 key points

  1. The agreement is extended until 2027 (art. 48.2 Ley 40/2015)
  2. The addendum is signed on 27 April 2026 (fecha firma adenda)

How it affects those involved

Research institutions proposing work on rare diseases will benefit from an extended evaluation period until 2027, with no new submission deadlines introduced.

Lifecycle

2026-05-08PublishedPublished in the BOE
2026-04-28Into forceComes into force (resolución de 28 de abril de 2026)
Official text Based on BOE data (boe.es). Information, not advice.

Does this provision affect you?

The subsidies team reviews your specific situation.

Talk to the subsidies team
This analysis is informational only and does not constitute legal advice or create a client-adviser relationship. BM Consulting.
Email
Contact